ReviewSpinal cord2026
NAD
Review in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
STUDY
designNarrative review and data-based perspective
objectivesCompare the current literature on poly(ADP-ribose) (PAR) polymerase (PARP) inhibition and NAD
methodsUsing a spinal cord contusion mouse model, a severe SCI was induced at the L1 spinal level in female C57Bl/6 J mice. 25 mg/kg PARP inhibitor (Veliparib), 750 mg/kg NR, or vehicle was administered intraperitoneally starting at 1 h post-injury (n = 13-18 mice per group), followed by daily treatments up to 8 days post-injury, and every other day thereafter until sacrifice (28 days post-injury). Functional recovery (by Basso Mouse Scale, BMS) and tissue-level effects were evaluated.
resultsFunctional recovery, lesion size (demyelinated (MBP), astrocyte (GFAP), and inflammatory (IBA1) area), and DNA damage load (γH2AX and PAR) did not improve with either Veliparib or NR treatment compared to vehicle-treated animals. Moreover, NR treatment decreased survival and increased astrogliosis in SCI mice compared to the vehicle control group.
conclusionsWithin the experimental paradigm, neither PARP inhibition nor NAD
Identifiers
42624965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.